Cypherpunk Technologies $CYPH Stake Boosted by Cygnus Capital Advisors LLC

Cygnus Capital Advisors LLC lifted its stake in Cypherpunk Technologies (NASDAQ:CYPH) by 2,044.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 246,460 shares of the company’s stock after acquiring an additional 234,968 shares during the quarter. Cygnus Capital Advisors LLC owned approximately 0.23% of Cypherpunk Technologies worth $151,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of CYPH. Simplify Asset Management Inc. purchased a new position in Cypherpunk Technologies in the fourth quarter valued at about $2,172,000. Acadian Asset Management LLC raised its stake in shares of Cypherpunk Technologies by 470.4% during the 1st quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company’s stock worth $389,000 after purchasing an additional 1,056,047 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Cypherpunk Technologies during the 1st quarter worth about $576,000. Geode Capital Management LLC acquired a new stake in shares of Cypherpunk Technologies during the 4th quarter valued at about $615,000. Finally, State Street Corp acquired a new stake in shares of Cypherpunk Technologies during the 4th quarter valued at about $163,000. 30.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Thomas Dietz sold 20,000 shares of Cypherpunk Technologies stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $1.72, for a total value of $34,400.00. Following the transaction, the director owned 132,500 shares of the company’s stock, valued at $227,900. This trade represents a 13.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.50% of the stock is currently owned by company insiders.

Cypherpunk Technologies Stock Performance

CYPH opened at $2.42 on Tuesday. The company has a market cap of $260.78 million, a PE ratio of 4.32 and a beta of 0.33. The stock has a 50-day moving average of $0.98 and a 200-day moving average of $0.88. Cypherpunk Technologies has a 52-week low of $0.27 and a 52-week high of $3.70.

Cypherpunk Technologies (NASDAQ:CYPH) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.18 earnings per share for the quarter.

Analysts Set New Price Targets

A number of research firms recently commented on CYPH. Weiss Ratings upgraded Cypherpunk Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $1.60 target price on shares of Cypherpunk Technologies in a research report on Thursday, August 27th. Finally, Wall Street Zen upgraded shares of Cypherpunk Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, July 4th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $1.60.

Cypherpunk Technologies Profile

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.